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Abstract
Background: Home monitoring has the potential to detect early pulmonary exacerbations in people with cystic
fibrosis (CF), with consequent improvements in health outcomes and healthcare associated costs. This study aims
to assess the effects of home monitoring on hospital admissions, quality of life, antibiotic requirements, exacerbation
frequency, lung function, nutritional outcomes, anxiety, depression, costs and health outcomes, as well as the
qualitative effects on the patient experience.
Methods: This randomised controlled mixed-methods trial aims to recruit 100 adults with CF cared for in one
large regional CF centre. Participants are randomly allocated 1:1 to the intervention group (twice-weekly home
monitoring of symptoms measured by the Cystic Fibrosis Respiratory Symptom Diary – Chronic Respiratory
Infection Symptom Score (CFRSD-CRISS) and Forced Expiratory Volume in one second (FEV1)) or a control group
(routine clinical care) for the 12-month study period. Measurements are recorded at study visits at baseline, 3, 6, 9
and 12 months. Spirometry, body weight, co-morbidities, medications, hospital inpatient days, courses of
antibiotics (oral and intravenous), pulmonary exacerbations (defined by the modified Fuchs criteria) are recorded
at each study visit. Health status, capability and health economics are measured at each study visit by the
Hospital Anxiety and Depression Scale (HADS), the ICEpop CAPability measure for Adults (ICECAP-A), EuroQol 5
dimensions (EQ-5D-5L) questionnaire and an adapted resource use questionnaire. The patient experience is
assessed by semi-structured qualitative interviews at baseline and 12 months.
Discussion: Results from this study will help to determine the effect of home monitoring on inpatient bed days
and quality of life in adults with CF, as well as other relevant health and health economic outcomes.
Trial registration: This study protocol is registered with Clinicaltrials.gov (NCT02994706), date registered 16th July 2014
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Background
Cystic fibrosis (CF) is the most common fatal inherited
condition in Caucasians, affecting more than 10,000 people
in the UK [1] and at least 70,000 people worldwide [2]. CF
is caused by abnormal function of the cystic fibrosis trans-
membrane conductance regulator (CFTR), a complex
protein which functions primarily as a chloride channel,
regulating movement of ions and fluid across epithelial
surfaces [3]. CFTR dysfunction causes epithelial secre-
tions to be abnormally dehydrated and viscous, result-
ing in damage to several organs including the lungs,
pancreas, intestines and liver. Within the lungs, chronic
infection and inflammation results in progressive lung
disease and premature death due to respiratory failure.
Survival in CF has dramatically improved over the last
40 years due to factors including improvements in anti-
biotic therapy, better nutrition and the development of
centres devoted to the provision of specialised CF care.
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As a result, CF has changed from a predominantly
paediatric disease to the current situation where the
majority of individuals with CF survive into adulthood.
The median predicted survival in the UK is currently in
excess of 45 years of age [1] and that of people with CF
born in the year 2000 is predicted to be in excess of
50 years of age [4].
People with CF often experience a burden of symptoms
on a daily basis, typically including: cough, sputum pro-
duction, wheeze, breathlessness, chest tightness and fever
[5]. When patients develop worsening symptoms, they are
advised to contact their CF multidisciplinary team (MDT)
and may be diagnosed with a pulmonary exacerbation.
Pulmonary exacerbations are typically treated with antibi-
otics targeted at the bacteria that cause chronic infection
in that individual patient. However, symptoms of a pul-
monary exacerbation do not usually develop suddenly, but
instead worsen slowly over the course of several days to
weeks. Patients presenting with less severe symptoms are
more likely to receive a course of oral antibiotics, but as
the exacerbation worsens the patient may require intra-
venous antibiotics. Intuitively, it would be expected that if
the patient were diagnosed with a pulmonary exacerbation
earlier, with milder symptoms, the requirement for intra-
venous antibiotics would be less.
Anecdotally we know that some patients are able to
perceive a change in their symptoms better than others.
Some realise that they are developing an exacerbation
early on, whereas others present when they have already
become more severely unwell. Additionally, patients may
know that they are developing an exacerbation, but are
unable to come to clinic due to other commitments or
due to a lack of clinic capacity. In either case, we suspect
that if we were able to diagnose the exacerbation at an
earlier stage we may be more likely to be able to treat it
successfully with a course of oral antibiotics, rather than
intravenous antibiotics. Additionally, in our experience if
the patient is less unwell they are more likely to be able
to receive intravenous antibiotics at home, rather than
requiring admission. This could potentially be beneficial
to the patient, preventing the complications of a more
severe infection and could also reduce healthcare ex-
penditure by averting a hospital admission.
Several previous studies have assessed the effect of tel-
ehealth or home monitoring in people with CF, but the
vast majority of these studies have been small feasibility
studies with limited external validity [6–13]. A rando-
mised pilot study in CF patients demonstrated that home
monitoring was able to detect more pulmonary exacerba-
tions than standard care [14]. A large randomised con-
trolled study of home monitoring is currently ongoing in
the USA, assessing the primary outcome of change in
forced expiratory volume in 1 s (FEV1) over a 12-month
period [15]. Secondary outcome measures include the
effect of home monitoring on CF respiratory symptom
scores, pulmonary exacerbations, health-related quality of
life, treatment burden, change in prevalence of resistant
strains of bacteria and adverse events. There are no cost-
effectiveness analyses included in this study and no quali-
tative assessment of the patient experience.
The primary aims of the current study are to (1) deter-
mine whether home monitoring is effective compared
with routine care in reducing hospital inpatient bed
days; and (2) assess whether this results in differences in
health-related quality of life over a 12 months period in
adults with CF. We hypothesise that participants ran-
domly allocated to home monitoring will require fewer
hospital inpatient bed days and that they will have better
health-related quality of life compared with those receiv-
ing routine care.
Methods/Design
Study design
This single-centre, non-blinded, randomised controlled
mixed-methods trial will be conducted at West Midlands
Adult CF Centre, Heart of England NHS Foundation
Trust, Birmingham, UK.
Participants
Inclusion/exclusion criteria
To be eligible for enrolment, participants must be able
to give informed consent, be aged ≥ 18 years and have a
diagnosis of CF confirmed by clinical characteristics, sweat
test and/or genetic testing. They must be clinically stable
at the time of recruitment (as assessed by the treating
physician) and have a history of at least one admission
to hospital to receive intravenous antibiotics over the
preceding 24 months.
Exclusion criteria include: 1) currently participating in
another clinical trial (excluding observational studies); 2)
pneumothorax or lung surgery within the previous 3 months
or eye surgery (e.g. cataract operation) in the previous
4 weeks (since these factors prevent measurement of
spirometry); 3) airway infection with Burkholderia cenoce-
pacia or Mycobacterium abscessus at the time of recruit-
ment; 4) previous lung transplantation procedure.
Sample size
Estimating the mean number of hospital inpatient days
is 42 for those receiving standard care and 36 for those
receiving monitoring, assuming a standard deviation of
10 and 40 patients per arm, approximate 95% confi-
dence intervals for these estimates would be (39, 45)
and (33, 39) respectively. To allow for patient drop out
a total of 100 patients will be recruited (50 patients in
each group).
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Recruitment and randomisation
The flow of participants through the study will reflect the
recommendations from the Consolidated Standards of
Reporting Trials statement [16] and is outlined in Fig. 1.
Participants will receive written and verbal information
explaining the study and written consent will be obtained
from all participants. West Midlands (Solihull) Research
Ethics Committee (12/WM/0379) approved the study,
Heart of England NHS Foundation Trust is the trial spon-
sor and the protocol is registered with Clinicaltrials.gov
(NCT02994706).
Participants will be screened from the West Midlands
Adult CF Centre database by the study investigators. If
eligible, the study investigators will approach patients
when they are attending routine clinic visits or during
inpatient admissions to explain the study and if they are
potentially interested they will be given the Participant
Information Sheet. Having had time to consider the study
and have any questions answered to their satisfaction, pa-
tients still keen to take part will be asked to provide writ-
ten informed consent. It will be explained that they may
withdraw from the study at any time.
At this point, baseline data will be obtained and the par-
ticipant will be asked to take part in a semi-structured
qualitative interview to assess the patient experience of
their care to date and their expectations of participating in
the study. Within strata, participants will then be randomly
assigned to receive either home monitoring or routine care.
The strata are based on the number of hospital admissions
to receive intravenous antibiotics over the preceding
24 months, separated into four strata: ‘1–2 admissions’,
‘3–4 admissions’, ‘5–6 admissions’ and ‘more than seven
admissions’. The randomisation will be completed by the
selection of randomly ordered sealed opaque envelopes,
with randomisation having been performed by a clerical
member of the CF team with no knowledge of the study.
Fig. 1 Flow of patients through the study
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Interventions
Routine care group
These participants will continue to receive routine CF
care, including regular outpatient clinic appointments
and inpatient admissions if required.
Home monitoring group
Participants randomized to receive home monitoring
will be provided with a Bluetooth-enabled digital spir-
ometer and a ‘Microsoft Windows Mobile’ enabled mo-
bile phone. Participants will be shown how to use the
equipment before going home. Participants will be asked
to record their FEV1 using a digital spirometer twice
weekly (Monday and Thursday), which will take around
5 min to complete. Participants will also record their
symptoms twice weekly (Monday and Thursday) on the
mobile phone by completing the Cystic Fibrosis Respira-
tory Symptom Diary – Chronic Respiratory Infection
Symptom Score (CFRSD-CRISS) [5]. This is a validated
disease-specific tool (consisting of 16 questions) designed
to detect symptoms of pulmonary exacerbations in CF,
taking around 5 min to complete.
Data regarding lung function and symptoms will be
automatically transmitted via a secure encrypted wireless
connection and the research team will be able to access
this data instantaneously on a specially designed website.
The mean values of the first 2 weeks’ data will be used
to determine the participants’ baseline levels for FEV1
and CFRSD-CRISS during the run-in phase. Following
this initial 2-week period, the CF team will receive an
email alert if participants’ FEV1 or symptoms deteriorate
below a set threshold. The criteria that will trigger an
email alert are one of: 1) a drop in FEV1 of 10% or more
from baseline; 2) total score of the CFRSD-CRISS worsen-
ing by more than three points from baseline. Following an
email alert, the CF team will contact the participant within
24 h to discuss their symptoms. Based on this discussion,
the research team will advise the participant on the best
management. If the participant needs to be assessed in the
outpatient clinic, we will arrange the next available con-
venient appointment. Depending on the clinical assess-
ment, participants will receive a course of antibiotics,
either oral or intravenous depending on the severity of
symptoms, sputum microbiology and patient choice. If
prescribed antibiotics, we will document whether these
were prescribed for a protocol-defined pulmonary exacer-
bation (see definition below).
To minimize lack of adherence to home monitoring,
we will re-enforce the importance of adhering to the
study protocol at each study visit. The system will alert
the research team if any participant fails to record symp-
toms and spirometry data. If this occurs, we will call the
participant to check if they are having any problems with
the equipment and that they are willing to proceed with
the study. If there are any difficulties with using the
equipment, we will explain how to resolve this issue. If
any participant fails to submit data for more than 20% of
occasions over any 28-day period we will advise them
that they risk being withdrawn from the study. If there
was a good reason for them not to submit data (such as
a foreign holiday of which we were not aware) we will
remind them to inform us if they will not be able to sub-
mit data. If the lack of data was due to non-adherence to
the study protocol and if the participant fails to submit
data for more than 20% of a subsequent 28-day period
they will be withdrawn from the study. If the participant
does not wish to proceed with the study at any stage
they will be withdrawn and this will have no adverse ef-
fect on their routine care.
In addition to recording their symptoms and spirom-
etry, subjects receiving home monitoring will be asked
to test a urine sample once every week and send a urine
sample in a prepaid envelope. These samples will be
batched and subsequently analysed for biomarker ana-
lysis and this data will not be used by the research team
during the course of this study.
Outcome measures
All outcome measures will be recorded at baseline, 3, 6,
9 and 12 months, except for the semi-structured qualita-
tive interview, which will be conducted at baseline and
at 12 months (Fig. 1). Baseline data collection will in-
clude age, gender, weight (kg), body mass index (kg/m2),
spirometry (FEV1, forced vital capacity (FVC)), concomi-
tant medications, co-morbidities and health economic
data. The number of courses of intravenous antibiotics
and hospital admissions per year in the previous 2 years
will also be recorded.
Primary outcomes measures
The primary outcome measures are number of hospital
inpatient bed days and health-related quality of life.
a) Hospital inpatient days will be defined by number
of complete 24-h periods between admission and
discharge.
b) Health-related quality of life will be measured by
the Cystic Fibrosis Questionnaire – Revised (CFQ-R),
a validated disease-specific health related quality of life
questionnaire [17], which consists of 49 self-reported
items within 12 domains: 1) physical functioning
(8 items); 2) vitality (4 items); 3) emotional functioning
(5 items); 4) eating disturbances (3 items); 5) treatment
burden (3 items); 6) general health perception (3
items); 7) social functioning (6 items); 8) body
image (3 items); 9) role limitations (4 items); 10)
weight problems (1 item); 11) respiratory symptoms
(6 items); and 12) digestive symptoms (3 items).
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Answers are reported on a four-point scale rating
frequency, difficulty, or truth and the scores range
from 0 to 100, with a higher score indicating better
quality of life.
Secondary outcome measures
a) Antibiotic requirements will be measured by total
number of completed days on oral and intravenous
antibiotics.
b) Protocol defined pulmonary exacerbations will be
recorded using the modified Fuchs criteria [18],
which requires the presence of 4 or more of the
following criteria:
· Change in sputum
· New or increased haemoptysis
· Increased cough
· Increased dyspnoea
· Malaise, fatigue, or lethargy
· Temperature above 38 °C
· Anorexia or weight loss
· Sinus pain or tenderness
· Change in sinus discharge
· Change in physical examination of the chest
· Decrease in pulmonary function by 10%
· Radiographic changes indicative of pulmonary
infection
c) Spirometry (FEV1, FVC) will be performed using a
digital Vitalograph spirometer in the CF outpatient
clinic in accordance with the American Thoracic
Society guidelines [19]. The highest value for FEV1
and FVC obtained from three reproducible trials will
be recorded and compared to predicted normal
values.
d) Body weight (kg) will be measured using digital
scales.
e) Body mass index (BMI) (kg/m2) will be measured
using body weight and height recorded using a
wall-mounted tape measure.
e) Anxiety and depression will be measured by the
Hospital Anxiety and Depression Scale (HADS) [20].
This questionnaire is designed to detect and measure
the severity of anxiety and depression. It consists of a
series of 14 statements, with responses based on a
4-point Likert scale. The HADS is self-administered,
with a higher score being indicative of greater anxiety
or depression.
f ) Health economics analysis will be conducted from a
NHS and patient perspective. Participants will be
asked to record any costs related to their care
throughout the study, including the cost of visiting
the hospital for outpatient visits (such as travel and
parking costs) and loss of pay due to time off work.
Participants will be asked to complete the EuroQol 5
dimensions (EQ-5D-5L), a generic health status
questionnaire [21] and ICEpop CAPability measure
for Adults (ICECAP-A), a generic measure of
capability [22] at baseline, 3, 6, 9 and 12-month
study visits. The researchers will record the costs
associated with caring for each participant (such
as costs of outpatient visits, inpatient admissions
and staff time) and the cost of conducting the
study (including staff costs and costs of the home
monitoring equipment).
Qualitative analysis
The qualitative aspects of the trial are a vital component
in allowing us to better understand the context in which
the trial takes place from the patient perspective. Partici-
pants will be invited to take part in semi-structured in-
terviews at baseline and 12-months. These will help us
to understand the reasons for patient participation, the
contexts in which the trial takes place and will support
interpretation of the findings (e.g. differential uptake or
use of home-monitoring, reasons for patient withdrawal).
Topics of inquiry at baseline will include how individ-
uals experience, understand and make decisions about
their symptoms, health-care needs and service use. Par-
ticipants’ expectations for home-monitoring will also be
explored. Follow-up interviews will be undertaken with
the intervention group to explore their experiences of
using home-monitoring, including issues around accept-
ability and sustainability. This will include questions to
explore the technical aspects of home-monitoring (e.g.
ease of use), behavioural issues (e.g. perceived costs and
benefits, necessary skill sets) and educational issues (e.g.
adequacy of information and training). Suggestions for
further improvement will also be sought. Where appro-
priate, follow-up interviews will examine reasons for
study withdrawal.
Statistical and data analysis
The outcomes listed will be summarized by group and
95% confidence intervals for these estimates will be cal-
culated. Exploratory analyses will include basic tests to
investigate differences between the intervention and con-
trol group, t-tests or chi-squared tests (or non-parametric
alternative as appropriate). Cost-effectiveness will be
assessed by calculating cost per reduction in hospital in-
patient bed days and cost per quality-adjusted life year
(QALYs) gained and appropriate sensitivity analyses will
be conducted. Interview transcripts will be imported into
NViVo and analysed using directed qualitative content
analysis [23] to interpret meaning from the interview data
in relation to the topics of inquiry, whilst allowing themes
to emerge inductively from the data. To optimise rigour,
data will be organized using the Framework method [24]
and analysed as part of team approach, with an audit trail
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kept throughout. The qualitative and quantitative findings
will be integrated using established methods [25] as part
of the final analysis to allow us to interpret, understand
and explain the trial findings.
Safety
The Trial Management Group (TMG) will be responsible
for day-to-day running of the trial and will meet on a
monthly basis to ensure that the study is running
smoothly. The Trial Steering Committee (TSC) will meet
every 3 months to ensure that the study is run ethically.
The Data Monitoring and Ethics Committee (DMEC) will
meet every 3 months and its responsibilities will include:
ensuring that the trial is recruiting subjects to schedule
and assessing any adverse events associated with home
monitoring. The DMEC can stop the trial early if felt ne-
cessary and will report to the Trial Steering Committee
after every meeting. The TMG, TSC and DMEC will func-
tion independently of the sponsor and funding bodies.
Discussion
People with CF typically suffer a progressive decline in
lung function, resulting in premature mortality, most
commonly due to respiratory failure [3]. Patients with
more frequent exacerbations experience a more rapid
decline in lung function and have a worse prognosis
[26]. In 25% of pulmonary exacerbations, the patient suf-
fers a permanent and irrecoverable loss of lung function
[27]. Strategies aiming to prevent and/or minimize the
impact of exacerbations are therefore vital for improving
patient outcomes. Reducing hospital admissions by de-
tecting early pulmonary exacerbations has the potential
not only to improve lung health, but also to improve
quality of life and reduce expenditure from the patient
and healthcare provider perspective. However, there are
also potential adverse effects of home monitoring, in-
cluding increased anxiety caused by increased patient
awareness of any deterioration in health status. This is
the first randomized controlled study to assess the effect
of home monitoring on relevant health outcomes com-
bined with the health economic impact and a robust as-
sessment of the patient experience.
The results of this study will allow people with CF and
their carers, as well as those funding CF care, to fully
evaluate the effect of home monitoring. This is particu-
larly relevant, since as the survival of people with CF
continues to improve, the feasibility of providing the
current standard model of regular face-to-face CF clin-
ical encounters becomes more challenging. Constraints
on healthcare budgets worldwide make the provision of
additional resources, including additional staff and new
CF centres less realistic. Novel means of using technology
to improve the interaction between people with CF
and their MDT provides a potential solution to this
increasingly difficult conundrum. Remote monitoring
also potentially reduces the requirement for hospital
visits and therefore could reduce opportunities for
cross-infection, although this must be balanced against
the theoretical benefits of regular direct patient contact
with the MDT. Importantly, this study will examine the
effect of home monitoring on psychological outcomes and
the patient experience, assessing potential adverse effects
such as increased anxiety, as well as potential benefits of
patients feeling more empowered by the greater know-
ledge of their own health status.
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